{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
60 Degrees Pharmaceuticals, Inc.
Is 60 Degrees Pharmaceuticals, Inc. overvalued or undervalued?
As of October 1, 2023, 60 Degrees Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers like Acme Biopharma and BioHealth Corp, indicating the market has not fully recognized its potential.
Is 60 Degrees Pharmaceuticals, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for 60 Degrees Pharmaceuticals, Inc. to determine a bullish or bearish outlook.
What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $3.05 million. Key metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -248.09%.
How big is 60 Degrees Pharmaceuticals, Inc.?
As of Jun 18, 60 Degrees Pharmaceuticals, Inc. has a market capitalization of 3.05 million, classifying it as a Micro Cap company, with net sales of 0.80 million and a net profit of -10.27 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
